All Oncology News

Anetumab ravtansine plus bevacizumab failed to improve efficacy vs paclitaxel plus bevacizumab in platinum-resistant high-grade ovarian cancer.

Results from SWOG S1815 showed no survival benefit for nab-paclitaxel plus gemcitabine and cisplatin in advanced biliary tract cancer.

Patients with BRAF V600E-mutant metastatic colorectal cancer experience poor clinical outcomes, according to real-world data.

T-DM1 was found to be tolerable, but progression-free survival was not improved vs historical data in HER2-positive biliary tract cancer.

A final analysis of the LIGHT trial showed olaparib demonstrated higher OS rates in patients with relapsed ovarian cancer who had germline or somatic BRCA mutations.

CAR T-cell therapies are associated with a risk for second primary cancers, and mitigation strategies for these toxic effects are warranted and under examination.

Marcia Cruz-Correa, MD, PhD, AGAF, FASGE, discusses the FDA approval of tislelizumab with chemotherapy for advanced gastric or GEJ adenocarcinoma.

MECCC Earns Three-Year Accreditation from the Commission on Cancer of the American College of Surgeons – Again!

The REZILIENT1 study of zipalertinib in pretreated patients with NSCLC harboring EGFR exon 20 insertion mutations met its primary end point of ORR.

Azenosertib (ZN-c3) monotherapy was active in heavily pretreated patients with cyclin E1–positive platinum-resistant ovarian cancer.

Findings from an oncogene overlap study in NSCLC support the potential clinical impact of high-level amplification of MET, HER2, and KRAS defined by NGS.

R. Lor Randall, MD, FACS, discusses the utility of routine intraoperative frozen section in soft tissue sarcomas and the impact of added costs.

Overall survival data were linked with baseline geriatric assessment and QOL scores in patients with metastatic pancreatic ductal adenocarcinoma.

Alexander Watson, MD, DPhil, FRCPC, explains how the relationship between driver positivity and amplification status affects same-gene alteration enrichment.

Peter Riedell, MD, details the safety and efficacy of rapcabtagene autoleucel in relapsed/refractory diffuse large B-cell lymphoma.

Patients with evidence of residual cancer in their blood after surgery, may benefit from adding of celecoxib to post surgery treatment.

Inavolisib plus palbociclib/fulvestrant improved OS vs palbociclib/fulvestrant alone in PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer.

177Lu-edotreotide prolonged PFS vs everolimus in patients with inoperable, progressive, grade 1 or 2 gastroenteropancreatic neuroendocrine tumors.

The combination of bezuclastinib and sunitinib generated favorable efficacy outcomes vs historical data in patients with previously treated GIST.

Treatment with daraxonrasib at the phase 3 dose of 300 mg was well tolerated, had favorable dose intensity, and showed efficacy in RAS–mutated PDAC.

The FDA approved T-DXd for unresectable/metastatic HR+, HER2-low/-ultralow breast cancer that progressed on endocrine therapy in the metastatic setting.

Detectable ctDNA after neoadjuvant chemotherapy was associated with the recommendation for TME in patients with T1-3, N0 low or mid rectal cancer.

Ashkan Emadi, MD, PhD, discusses early efficacy signals with venetoclax plus pegcrisantaspase in relapsed/refractory AML.

A longer-term follow-up analysis showed that adagrasib/cetuximab demonstrated clinically meaningful efficacy in KRAS G12C–mutated advanced CRC.

Updated phase 2 data revealed fruquintinib plus TAS-102 could offer survival benefits in pretreated metastatic colorectal cancer.

The EMA has accepted for review an MAA seeking the approval of nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with CIS.

The FDA has granted priority review to belzutifan for advanced pheochromocytoma and paraganglioma.

Weiran Feng, PhD, Assistant Professor in the Nuclear Dynamics and Cancer Research Program and a member of the Cancer Epigenetics Institute (CEI).

A recap of the top data presented at the 2025 Gastrointestinal Cancers Symposium.

Although 83.7% of treatment decisions remained unchanged, findings from Signatera influenced adjuvant chemotherapy usage in 16.3% of cases for stage II/III CRC.